IL17A and psoriasis: Relative to IMQ‐treated Adrb1fl/fl control mice, IMQ‐treated Adrb1fl/flTrdc‐Cre mice had significantly reduced back‐skin thickness, erythema, scaling and total Psoriasis Area and Severity Index (PASI) scores, and inflammatory infiltration and IL‐17+ dermal γδT cells (Figure 5d–g).